Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

PSMA Expression is Highly Homogenous in Primary Prostate Cancer

PSMA Expression is Highly Homogenous in Primary Prostate Cancer RESEARCH ARTICLE PSMA Expression is Highly Homogenous in Primary Prostate Cancer Maria C. Tsourlakis, MD,* Franka Klein,* Martina Kluth, MSc,* Alexander Quaas, MD,* Markus Graefen, MD, PhD,w Alexander Haese, MD, PhD,w Ronald Simon, PhD,* Guido Sauter, MD, PhD,* Thorsten Schlomm, MD, PhD,wz and Sarah Minner, MD* (Appl Immunohistochem Mol Morphol 2015;23:449–455) Background: Prostate-specific membrane antigen (PSMA) is a suggested target for antibody-based therapy of prostate cancer, potentially involved in the regulation of cell migration. As het- orldwide >220,000 men die annually of prostate erogeneity may limit the applicability of targeted therapies, this Wcancer, usually as a result of complications of meta- study was undertaken to estimate the degree of heterogeneity of stases. Today, androgen ablation (hormonal therapy) is PSMA expression in prostate cancer. the first-line therapy for metastatic prostate cancer, result- Methods: For heterogeneity analysis, a prostate cancer hetero- ing in a transient reduction of symptoms and tumor pro- geneity TMA containing samples from 10 different tumor blocks gression until these cancers become androgen-independent of 189 consecutive prostate cancers was used. PSMA expression and rapidly progressive. Androgen-independent prostate was analyzed by immunohistochemistry. cancer is only moderately sensitive to chemotherapy. The striking success of new targeted drugs raise the Results: http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

PSMA Expression is Highly Homogenous in Primary Prostate Cancer

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/psma-expression-is-highly-homogenous-in-primary-prostate-cancer-rmdBAT00mf

References (54)

Copyright
Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000110
pmid
26153794
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE PSMA Expression is Highly Homogenous in Primary Prostate Cancer Maria C. Tsourlakis, MD,* Franka Klein,* Martina Kluth, MSc,* Alexander Quaas, MD,* Markus Graefen, MD, PhD,w Alexander Haese, MD, PhD,w Ronald Simon, PhD,* Guido Sauter, MD, PhD,* Thorsten Schlomm, MD, PhD,wz and Sarah Minner, MD* (Appl Immunohistochem Mol Morphol 2015;23:449–455) Background: Prostate-specific membrane antigen (PSMA) is a suggested target for antibody-based therapy of prostate cancer, potentially involved in the regulation of cell migration. As het- orldwide >220,000 men die annually of prostate erogeneity may limit the applicability of targeted therapies, this Wcancer, usually as a result of complications of meta- study was undertaken to estimate the degree of heterogeneity of stases. Today, androgen ablation (hormonal therapy) is PSMA expression in prostate cancer. the first-line therapy for metastatic prostate cancer, result- Methods: For heterogeneity analysis, a prostate cancer hetero- ing in a transient reduction of symptoms and tumor pro- geneity TMA containing samples from 10 different tumor blocks gression until these cancers become androgen-independent of 189 consecutive prostate cancers was used. PSMA expression and rapidly progressive. Androgen-independent prostate was analyzed by immunohistochemistry. cancer is only moderately sensitive to chemotherapy. The striking success of new targeted drugs raise the Results:

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Jul 1, 2015

There are no references for this article.